[Clinical studies on intravenous drip-infusion of micronomicin for complicated urinary tract infections].
The clinical efficacy and safety of intravenous micronomicin (MCR) therapy were evaluated in cases with complicated urinary tract infections. MCR was administered to 13 patients by intravenous drip infusion over a period of 1 hour, in a dose of 120 mg twice daily for 5 consecutive days. Therapeutic results were evaluated by the criteria proposed by UTI committee and the judgement of the doctor in charge and the overall clinical efficacy rate was 69% (9/13) and 85% (11/13), respectively. Among 18 strains isolated before treatment, 15 strains were eradicated and bacteriological efficacy rate was 83%. No side effects including nephrotoxicity and ototoxicity associated with the treatment were noted, except for 1 case with transient elevation of A1-P.
D000328:Adult; D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D005260:Female; D005839:Gentamicins; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins; C037545:micronomicin